secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950170-24-097007
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics Q2 net loss $48.1M; workforce cut 75%; ENLIGHTEN 1 subgroup positive
--------------------------------------------------------------------------------

- Q2 net loss $48.1M vs $15.6M YoY, including $22.8M right-of-use asset impairment and $6.5M restructuring charge.
- Cash $67.5M at June 30; expects runway into Q1 2026.
- Further analysis of ENLIGHTEN 1 shows LYR-210 improved 3CS score by 2.25 points (p=0.0058) vs sham in CRS with nasal polyps.
- Reduced workforce by ~75% (87 employees), halted manufacturing, paused LYR-220, and seeking subleases.
- ENLIGHTEN 1 extension results expected Q4 2024; ENLIGHTEN 2 topline results expected 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017024097007/0000950170-24-097007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017024097007/lyra-20240814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-097007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer